2014 Analysis of Mexican Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies

November 2013 | 510 pages | ID: 2D7C2EF8875EN
Venture Planning Group

Abstracts

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350.

2014 Analysis of Mexican Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the Mexican cancer diagnostics market during the next five years. The report examines trends in the Mexico cancer diagnostics market; reviews current and emerging tests; analyses potential applications of various diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

RationaleThe cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Cancer Diagnostic Tests Over 200 current and emerging assays, including:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

• Market shares of major suppliers.
• Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:
• Hospitals
• Commercial/Private LaboratoriesCurrent and Emerging Products
• Review of over 200 current and emerging cancer diagnostic tests,including:
• Biochemical Markers
• Oncogenes
• Growth Factors
• Hormones
• Colony Stimulating Factors
• Lymphokines
• Immunohistochemical Stains, and others.

Analysis of major immunoassay analyzers used forcancer diagnostic testing, including their operating characteristics,features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT,artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments ofmajor suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 510 pages and 58 tables

Contents

I. INTRODUCTION

II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
  ADA
  B-Protein
  PNP
  5'-Nucleotidase
27. Oncogenes
  Abl/abl-bcr
  AIB1
  BCL-2
  BRCA1
  CD44
  C-fos
  C-myb
  C-myc
  CYP-17
  Erb-B
  HPC1
  N-myc
  P40
  P51
  P53
  PIK3CA
  PTI-1
  Ras
  Reg
  Sis
  Src
28. Polypeptide Growth Factors
  Basic Fibroblast Growth Factor
  Beta-TGF
  Cachectin (TNT)
  Calmodulin
  ECFR
  Nerve Growth Factor (NGF)
  Epidermal Growth Factor (EGF)
  Ornithine Decarboxylase
  Transferrin
  Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
  Alpha-Interferon
  B Cell Growth Factors
  B Cell Growth Factor (BCGF)
  Gamma-Interferon
  Interleukin-1 (IL-1)
  Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
  N-Acetylglucosamine
  Actin
  Alpha-Actin
  Antineuronal Antibodies
  7B2
  B72.3
  Bax
  BCD-F9
  BLCA-4
  Blood Group Antigens A,B,H
  CA 50
  CA 72-4/TAG-72
  CA 195
  CA-242
  CA-549
  CAM 26
  CAR-3
  Cathepsin-D
  Chromogranin A and B
  Cluster 1 Antigen
  Cluster-5/5A Antigen
  CTA
  CU18
  DR-70
  DU-PAN-2
  Endometrial Bleeding Associated Factor
  Endostatin
  Epithelial Membrane Antigen
  Feulgen Hydrolysis
  Fibronectin
  FSH
  (1->3)-L-fucosyltransferase
  Gastrin-Releasing Peptide (GRP)
  GDCFP-15
  Glucagon
  Glycoamines
  H23
  Her-2
  Human Carcinoma Antigen
  HPA
  HSP27
  Intermediate Filaments
  Cytokeratins/CK18/Cyfra 21-1
  Desmin
  Gliofibrillary Acid Protein
  Neurofilaments
  Vimentin
  KA 93
  Kinases
  KP16D3
  LAI
  Leukocyte Common Antigen
  Lewis Antigens
  Lysophosphatidic Acid (LPA)
  Ma 695/Ma 552
  MABDF3
  MAG
  ME1
  Minactivin
  MN/CA9
  MSA
  Mucin Cancer Antigen (MCA)
  Multiple Tumor Suppressor 1
  Myosin
  NEA-130
  NMP22
  OA-519
  Opiod Peptides
  P-glycoprotein
  Pancreatic Oncofetal Antigen (POA)
  Placental Lactogen
  PR92
  Proliferative Index, Ki-67
  Px
  RB Inactivation/Deletion
  Ret
  SCCL 175
  Selectin
  Sialic Acid
  Sialyl SSEA-1/SLX
  SN10
  Somatostatin
  TA-90
  TABA
  Tachykinin
  TAG 12
  TPS
  Troponin
  Tubulin
  VCAM
  VEGF
  Villen

B. INSTRUMENTATION REVIEW AND MARKET NEEDS

C. CURRENT AND EMERGING TECHNOLOGIES

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
  a. Technological Principle
  b. Radioimmunoassay (RIA)
  c. Enzyme Immunoassays (EIA)
    Overview
    ELISA
    Immunofiltration
    Particle-Membrane Capture Immunoassay
    Enzyme Amplification
  d. Fluorescent Immunoassays
  e. Luminescence
    Chemiluminescence
    Bioluminescence
  f. Latex Agglutination
  g. Immunoprecipitation
  h. Affinity Chromatographu
  e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
  a. Technology Overview
  b. Amplification Methods
4. Chromosome Analysis
  a. Chronic Myelogenous Leukemia (CML)
  b. Acute Myeloid Leukemia (AML)
  c. Acute Lymphoblastic Leukemia (ALL)
  d. Malignant Lymphomas Lymphoid Malignancies
  e. Chronic Lymphocytic Leukemia (CLL)
  f. Solid Cancers
  g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
  a. CT
  b. MRI
  c. NMR
  d. PET
  e. Photonics Spectroscopy

D. PERSONAL TESTING

III. MEXICO: MARKET SIZE, GROWTH, AND MAJOR SUPPLIERS’ SHARES

X. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. REAGENT KITS AND TEST SYSTEMS/PANELS

B. INSTRUMENTATION

C. COMPUTERS, SOFTWARE AND AUTOMATION

D. AUXILIARY PRODUCTS

XI. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XII. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. INTERNAL DEVELOPMENT

B. COLLABORATIVE ARRANGEMENTS

C. UNIVERSITY CONTRACTS

D. DISTRIBUTION STRATEGIES

1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor

XIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. MARKET MATURITY

B. COST CONTAINMENT

C. COMPETITION

D. TECHNOLOGICAL EDGE AND LIMITATIONS

E. PATENT PROTECTION

F. REGULATORY CONSTRAINTS

G. DECENTRALIZED TESTING MARKET CHALLENGES

XIV. COMPETITIVE PROFILES

  Abbott
  AdnaGen
  Agilent Technologies
  Applied Gene Technologies
  Arca/Nuvelo
  Beckman Coulter/Danaher
  Becton Dickinson
  Biomedical Diagnostics
  bioMerieux
  Bio-Rad
  CellSearch
  Cepheid
  Correlogic Systems/Vermillion
  Decode
  Diadexus
  Diagnocure
  Diasorin
  Eiken Chemical
  Epigenomics
  Enterix
  Enzo Biochem
  Exact Sciences
  Fujirebio/Innogenetics
  Guided Therapeutics
  Hologic/Gen-Probe
  Kreatech
  Kyowa Medex
  Life Technologies
  Mackay Life Sciences
  Myriad Genetics
  Nanogen Elitech
  OncoLab
  Ortho-Clinical Diagnostics
  Panacea Pharmaceuticals
  Polartechnics
  Polymedco
  PreMD
  Qiagen/Ipsogen
  Quest Diagnostics
  Radient Pharmaceuticals
  Roche
  Scienion
  Sequenom
  Siemens Healthcare
  Takara Bio
  Targeted Diagnostics & Therapeutics
  Tosoh
  Veridex
  Wako Pure Chemicals
  Wallac/PE
  Zila

XV. APPENDIXES: APPENDIX: MAJOR UNIVERSITIES AND RESEARCH

  Centers Developing Cancer Diagnostic Technology and Applications

List Of Tables

LIST OF TABLES

Tudor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis

EXECUTIVE SUMMARY TABLE:

Mexico, Total Cancer Diagnostic Test Volume and Sales Forecast by Market Segment
Mexico, Laboratories Performing Cancer Diagnostic Tests by Market Segment
Mexico, Total Estimated Cancer Diagnostic Test Volume Forecast by Market Segment
Mexico, All Market Segments Estimated Cancer Diagnostic Test Volume Forecast
Mexico, Hospital Laboratories Estimated Cancer Diagnostic Test Volume Forecast by Test
Mexico, Commercial/Private Laboratories Estimated Cancer Diagnostic Test Volume Forecast
Mexico, Total Estimated Cancer Diagnostic Sales Forecast by Market Segment
Mexico, All Market Segments Estimated Cancer Diagnostic Sales Forecast by Test
Mexico, Hospital Laboratories Estimated Cancer Diagnostic Sales Forecast by Test
Mexico, Commercial/Private Laboratories Estimated Cancer Diagnostics Market Forecast by Test
Mexico, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market
Mexico, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Lymphocyte Subtyping Test Volume And Diagnostics Sales Forecast by Market Segment
Mexico, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Progesterone Receptor Test Volume And Diagnostics Sales Forecast by Market Segment
Mexico, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, TPA Test Volume and Diagnostics Sales Forecast by Market Segment
Mexico, Cancer Diagnostics Market Estimated Shares Of Major Suppliers